BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18471943)

  • 1. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus.
    Muthumani K; Lankaraman KM; Laddy DJ; Sundaram SG; Chung CW; Sako E; Wu L; Khan A; Sardesai N; Kim JJ; Vijayachari P; Weiner DB
    Vaccine; 2008 Sep; 26(40):5128-34. PubMed ID: 18471943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
    Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.
    García-Arriaza J; Cepeda V; Hallengärd D; Sorzano CÓ; Kümmerer BM; Liljeström P; Esteban M
    J Virol; 2014 Mar; 88(6):3527-47. PubMed ID: 24403588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
    Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
    J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice.
    Tretyakova I; Hearn J; Wang E; Weaver S; Pushko P
    J Infect Dis; 2014 Jun; 209(12):1882-90. PubMed ID: 24585894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
    Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
    J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine.
    Bao H; Ramanathan AA; Kawalakar O; Sundaram SG; Tingey C; Bian CB; Muruganandam N; Vijayachari P; Sardesai NY; Weiner DB; Ugen KE; Muthumani K
    Viral Immunol; 2013 Feb; 26(1):75-83. PubMed ID: 23409931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
    Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
    J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
    Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
    J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
    Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
    Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of Chikungunya virus.
    Vega-Rúa A; Zouache K; Girod R; Failloux AB; Lourenço-de-Oliveira R
    J Virol; 2014 Jun; 88(11):6294-306. PubMed ID: 24672026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
    Arévalo MT; Huang Y; Jones CA; Ross TM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chikungunya virus and the mosquito vector Aedes aegypti in New Caledonia (South Pacific Region).
    Dupont-Rouzeyrol M; Caro V; Guillaumot L; Vazeille M; D'Ortenzio E; Thiberge JM; Baroux N; Gourinat AC; Grandadam M; Failloux AB
    Vector Borne Zoonotic Dis; 2012 Dec; 12(12):1036-41. PubMed ID: 23167500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-boost immunization strategies against Chikungunya virus.
    Hallengärd D; Lum FM; Kümmerer BM; Lulla A; Lulla V; García-Arriaza J; Fazakerley JK; Roques P; Le Grand R; Merits A; Ng LF; Esteban M; Liljeström P
    J Virol; 2014 Nov; 88(22):13333-43. PubMed ID: 25210177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling.
    Partidos CD; Weger J; Brewoo J; Seymour R; Borland EM; Ledermann JP; Powers AM; Weaver SC; Stinchcomb DT; Osorio JE
    Vaccine; 2011 Apr; 29(16):3067-73. PubMed ID: 21300099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.
    Chu H; Das SC; Fuchs JF; Suresh M; Weaver SC; Stinchcomb DT; Partidos CD; Osorio JE
    Vaccine; 2013 Jul; 31(33):3353-60. PubMed ID: 23727003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
    Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
    J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model.
    Campos RK; Preciado-Llanes L; Azar SR; Kim YC; Brandon O; López-Camacho C; Reyes-Sandoval A; Rossi SL
    Front Immunol; 2020; 11():591885. PubMed ID: 33224148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design.
    Taylor A; Liu X; Zaid A; Goh LY; Hobson-Peters J; Hall RA; Merits A; Mahalingam S
    mBio; 2017 Feb; 8(1):. PubMed ID: 28223458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological correlates of immune protection conferred by Chikungunya virus infection.
    Sheela PJ; Sumathy K
    Acta Virol; 2013; 57(4):471-3. PubMed ID: 24294963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.